epoetin + iron

**epoetin + iron** is a combination therapy consisting of *epoetin* (recombinant human erythropoietin) and *iron supplementation*, commonly administered intravenously, used primarily for the treatment of anemia associated with chemotherapy or chronic kidney disease. **Epoetin** stimulates erythropoiesis by promoting the division and differentiation of erythroid progenitors in the bone marrow, thereby increasing red blood cell production[2][3][4]. **Iron supplementation** provides the necessary iron required for hemoglobin synthesis, and its combination with epoetin addresses both inadequate erythropoietin activity and functional iron deficiency, improving therapeutic response when anemia is unresponsive to epoetin alone[1][4]. The main indication is for chemotherapy-induced anemia, particularly in patients who fail to respond sufficiently to epoetin monotherapy due to iron deficiency. The regimen aims to raise hemoglobin levels, reduce the need for transfusions, and improve quality of life[1].

Brand names

RetacritSilapo

Other names

epoetin plus ironerythropoietin + ironEPO + iron